← Leaderboards
Joseph Benjamin Rucker
Villanova University
$9,079,205
Attributed
$9,206,880
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2009–24$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$9,206,880 · 11
By mechanism
R44$6,155,185 · 4
R43$2,914,345 · 6
R15$137,350 · 1
Top collaborators
- Chester Edward Markwalter1 shared
Others in their field
Top investigators on “Antibodies”
- Lawrence Corey · Fred Hutchinson Cancer Center$525,765,536
- Bambra Strokes · Ppd Development Lp$461,655,950
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$385,009,925
- Barton F Haynes · Duke University$372,611,596
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$323,573,074
- Dennis R. Burton · Scripps Research Institute$306,733,901
Research focus
AntibodiesProteinsSpecificityTherapeutic Monoclonal AntibodiesMonoclonal AntibodiesMembrane ProteinsStructureFamily MemberEngineeringBaseAbbreviationsIon ChannelComplexSmall MoleculeHuman DiseasePharmaceutical PreparationsLeadAmericanTechnologyAffinityMutagenesisPharmacologic SubstanceSuccessEpitopes
Grant awards (23)
Development of Claudin MAbs for Treating Solid Tumors$394,721
R44 · FY2024 · CA · contact PI
Development of Claudin MAbs for Treating Solid Tumors$709,264
R44 · FY2023 · CA · contact PI
Development of Claudin MAbs for Treating Solid Tumors$599,881
R44 · FY2022 · CA · contact PI
Development of Kv1.3 Monoclonal Antibodies Targeting TEM Cells for Treating Autoimmune Disorders$589,456
R44 · FY2022 · GM · contact PI
Development of Kv1.3 Monoclonal Antibodies Targeting TEM Cells for Treating Autoimmune Disorders$634,330
R44 · FY2021 · GM · contact PI
Development of Nav1.7 Monoclonal Antibodies for Treating Pain$474,833
R43 · FY2021 · NS · contact PI
Sustained Release Formulations of Therapeutic Antibodies$255,351
R43 · FY2021 · GM
Development of Kv1.3 Monoclonal Antibodies Targeting TEM Cells for Treating Autoimmune Disorders$585,859
R44 · FY2020 · GM · contact PI
Identifying Agonist MAbs against GPCRs$132,158
R43 · FY2019 · GM · contact PI
Identifying Agonist MAbs against GPCRs$223,202
R43 · FY2018 · GM · contact PI
Development of P2X3 Ion Channel MAbs for the Treatment of Pain$215,291
R44 · FY2016 · GM · contact PI
Engineering of membrane protein chemosensors for therapeutic research$212,267
R44 · FY2016 · DC · contact PI
Development of P2X3 Ion Channel MAbs for the Treatment of Pain$652,090
R44 · FY2015 · GM · contact PI
Engineering of membrane protein chemosensors for therapeutic research$492,209
R44 · FY2015 · DC · contact PI
Development of High-expressing Ion Channels for Research and Therapeutic Applicat$207,740
R43 · FY2015 · GM · contact PI
Development of P2X3 Ion Channel MAbs for the Treatment of Pain$561,078
R44 · FY2014 · GM · contact PI
Engineering of membrane protein chemosensors for therapeutic research$508,739
R44 · FY2014 · DC · contact PI
Development of High-expressing Ion Channels for Research and Therapeutic Applicat$264,005
R43 · FY2014 · GM · contact PI
Isolation of Monoclonal Antibodies against Membrane Proteins$338,347
R43 · FY2012 · GM · contact PI
Isolation of Monoclonal Antibodies against Membrane Proteins$322,466
R43 · FY2011 · GM · contact PI
Development of taste receptor ligands using structure-activity studies$373,651
R43 · FY2010 · DC · contact PI
Development of taste receptor ligands using structure-activity studies$322,592
R43 · FY2009 · DC · contact PI
Biochemical studies of retroviral receptor pseudotypes$137,350
R15 · FY2002 · GM